Health ministries currently lack effective tools for monitoring and evaluation of schistosomiasis control programmes. Egg detection can be used, but the cost, challenges of obtaining samples, and the need for trained personnel and equipment limit the frequency of monitoring. The purpose of this TPP ...is to guide the development of new diagnostic tools to reliably measure when prevalence is above or below a cut-off of 10% in school-aged children. Communities remaining above 10% require annual MDA, while communities below 10% can reduce MDA frequency as long as < 10% prevalence can be maintained. However, the lack of a reliable test has hindered the development of maintenance strategies. The test is also needed to track changes of prevalence > 10% to ensure that annual MDA is reducing overall prevalence.
more
Issue Brief no.15, September 2021, updated 19 October 2021
In the Region of the Americas, the leishmaniases are a group of diseases caused by various species of Leishmania, which cause a set of clinical syndromes in infected humans that can involve the skin, mucosa, and visceral organs. The spectrum of clinical disease is varied and depends on the interacti...on of several factors related to the parasite, the vector, and the host. Cutaneous leishmaniasis is the form most frequently reported in the Region and nearly 90% of cases present single or multiple localized lesions. Other cutaneous clinical forms, such as disseminated and diffuse cutaneous leishmaniasis, are more difficult to treat and relapses are common. The mucosal form is serious because it can cause disfigurement and severe disability if not diagnosed and treated early on. Visceral leishmaniasis is the most severe form, as it can cause death in up to 90% of untreated people.
more
La presente publicación describe las medidas de bioseguridad para disminuir el riesgo de infección por COVID-19 durante la atención estomatológica., así como las actividades y procedimientos del personal que brinda atención estomatológica para disminuir el riesgo de infección por COVID-19.
In 2015, to advance the global and national response to antimicrobial resistance (AMR), the World Health Assembly issued resolution WHA68.7 calling for all Member States to develop AMR national action plans that address the five objectives of the World Health Organization Global Action Plan (GAP) by... May 2017. The WHO GAP provides a framework to support countries in developing their national action plans on AMR. To operationalize and accelerate implementation of national action plans on AMR, WHO has developed a costing and budgeting tool and accompanying user guide. The purpose is to support countries in costing prioritized activities of an operational plan linked to their AMR national action plan, and identify existing funding and funding gaps to promote resource mobilization and sustainable implementation. The target audience of the publication are national policy makers and designated costing coordinators for national action plans on AMR.
more
The Strategic Tool for Assessing Risks (STAR) offers a comprehensive, easy-to-use toolkit and approach to enable national and subnational governments to rapidly conduct a strategic and evidence-based assessment of public health risks for planning and prioritization of health emergency preparedness a...nd disaster risk management activities. This guidance describes the principles and methodology of STAR to enhance its adaptation and use at the national or subnational levels.
more
This publication presents a comprehensive methodology to support the Member States of the Pan American Health Organization (PAHO) in preparing for and responding to heat-health risks in the Region of the Americas. It builds on World Health Organization and the World Meteorological Organization globa...l documents, as well as on the disaster preparedness methodologies employed throughout the countries of the Region. This publication is part of an effort coordinated by PAHO to support Member States in multihazard preparedness, and includes: early warning system strengthening; threat characterization; activation and deactivation procedure definition; and institutional coordination. It engages different disciplines and recognizes the importance of intersectoral collaboration to respond to heat-health risks. It aims to bring awareness of the impacts of heat on the health of people of the Americas to public health decisionmakers, and thereby strengthen health service provision.
more
En esta publicación se presenta un método integral para brindar apoyo a los Estados Miembros de la Organización Panamericana de la Salud (OPS) en la preparación para la respuesta a los riesgos para la salud relacionados con el calor en la Región de las Américas. Se basa en los documentos de al...cance mundial de la Organización Mundial de la Salud y la Organización Meteorológica Mundial, así como en los métodos de preparación para hacer frente a desastres aplicados en todos los países de la Región. La presente publicación forma parte de un esfuerzo coordinado por la OPS para ayudar a los Estados Miembros a prepararse para hacer frente a múltiples amenazas e incluye el fortalecimiento de los sistemas de alerta temprana; la caracterización de la amenaza; la definición de los procedimientos de activación y desactivación, y la coordinación institucional. Abarca diferentes disciplinas y reconoce la importancia de la colaboración intersectorial para responder a los riesgos para la salud relacionados con el calor. Procura sensibilizar a las autoridades de salud pública acerca de los efectos del calor sobre la salud de la población de la Región de las Américas y de esa manera fortalecer la prestación de los servicios de salud.
more
The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.
Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij...ing Wantai’s TB-IGRA and Qiagen QuantiFERON-TB Gold Plus products. This expands the range of tests available to detect TB infection. Full details are provided in this WHO policy statement.
more
his guidance provides interim guidance for the integration of SARS-CoV-2 and influenza virologic and genomic surveillance, from sentinel site case enrolment and sampling to the eventual sharing of the virus sequence data, a process known as end-to-end surveillance. This guidance builds on experience...s and lessons learned as countries adapted their influenza surveillance systems in the context of the COVID-19 pandemic and reviews new evidence to provide guidance on end-to-end surveillance. The guidance includes new algorithms and strategies to adapt sentinel systems to make them resilient and agile for addressing global and national surveillance needs for influenza and COVID-19.covid-
more
Laboratory Safety Handbook. Global edition
Las pruebas de cultivo y sensibilidad a fármacos son necesarias especialmente para los pacientes con riesgo de tuberculosis resistente a los medicamentos y para vigilar su respuesta al tratamiento. Si bien el cultivo y las pruebas de sensibilidad son ca...da vez más accesibles, la infraestructura para realizarlos es compleja y requiere equipos especializados y costosos. Con vistas a garantizar que el personal de laboratorio realice su trabajo de forma correcta y segura, este manual ofrece una guía práctica mediante textos sencillos e ilustraciones claras que ayudan a comprender los problemas de seguridad conexos. De ahí la importancia de su publicación en español para la red de laboratorios nacionales y supranacionales que apoya la Organización Panamericana de la Salud en la Región de las Américas.
more
The report notes that the number of people in need of one or more assistive products is likely to rise to 3.5 billion by 2050, due to populations ageing and the prevalence of noncommunicable diseases rising across the world. The report also highlights the vast gap in access between low- and high-inc...ome countries. An analysis of 35 countries reveals that access varies from 3% in poorer nations to 90% in wealthy countries.
Affordability is a major barrier to access, the report notes. Around two thirds of people with assistive products reported out-of-pocket payments for them. Others reported relying on family and friends to financially support their needs.
more
Here you can find the latest reports